You might also like
Humana Inc., headquartered in Louisville, Kentucky, is a leading health and well-being company that operates primarily through its Insurance and CenterWell segments. The company provides a wide range of health insurance products, including medical, dental, hearing, vision, and prescription drug coverage, with a significant emphasis on Medicare Advantage, Medicaid, and Military offerings . Additionally, Humana offers health services through its CenterWell segment, which includes pharmacy solutions, primary care, and home health services, along with strategic partnerships to develop senior-focused primary care centers .
-
Insurance - Offers a comprehensive range of health insurance products, focusing on Medicare Advantage, Medicaid, and Military offerings, as well as dental, hearing, vision, and prescription drug coverage .
- Medicare Advantage - Provides enhanced health insurance plans for seniors, focusing on comprehensive care and additional benefits.
- Medicaid and Military - Delivers health insurance solutions tailored for Medicaid recipients and military personnel.
-
CenterWell - Delivers health services, including pharmacy solutions, primary care, and home health services, with a focus on senior care through strategic partnerships .
- Pharmacy Solutions - Offers medication management and pharmacy services to improve patient outcomes.
- Primary Care - Provides primary healthcare services with an emphasis on senior-focused care centers.
- Home Health Services - Offers in-home healthcare services to support patient recovery and well-being.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Bruce D. Broussard ExecutiveBoard | CEO (until July 1, 2024) | Board Member at HP Inc.; Trust for the National Mall; AHIP | CEO since 2013, leading Humana's integrated care delivery model. Transitioning out of the role on July 1, 2024. | |
James A. Rechtin ExecutiveBoard | President and CEO (effective July 1, 2024) | None | Joined Humana as President and COO in January 2024. Will succeed Bruce Broussard as CEO on July 1, 2024. Previously CEO of Envision Healthcare. | |
Celeste Mellet Executive | CFO | None | Appointed CFO in January 2025. Previously CFO at Global Infrastructure Partners and Evercore. | |
George Renaudin II Executive | President, Medicare & Medicaid | None | President of Medicare & Medicaid since February 2024. | |
John-Paul W. Felter Executive | Chief Accounting Officer & Controller | None | Elected Chief Accounting Officer in August 2022. | |
Joseph C. Ventura Executive | Chief Legal Officer | None | Chief Legal Officer since February 2019. | |
Samir M. Deshpande Executive | Chief Information Officer | None | Joined Humana in 2017. Previously Chief Technology and Risk Officer. | |
Timothy S. Huval Executive | Chief Administrative Officer | None | Joined Humana in 2012. Previously Chief Human Resources Officer. | |
Vishal Agrawal, M.D. Executive | Chief Strategy and Corporate Development Officer | None | Joined Humana in December 2018. Previously President and Chief Growth Officer at Ciox Health. | |
William K. Fleming Executive | Chief Corporate Affairs Officer | None | Joined Humana in 1994. Previously Segment President, Pharmacy Solutions. | |
Brad D. Smith Board | Independent Director | President of Marshall University; Board Member at Amazon and Intuit | Independent Director since 2022. Former CEO and Executive Chairman of Intuit. | |
Frank A. D’Amelio Board | Independent Director | Board Member at Zoetis, Hewlett Packard Enterprises, and Catalent | Independent Director since 2003. Chair of the Audit Committee. | |
John W. Garratt Board | Independent Director | Board Member at Papa John’s, Cracker Barrel, and Federal Reserve Bank of Atlanta | Independent Director since 2020. Former CFO of Dollar General. | |
Jorge S. Mesquita Board | Independent Director | Board Member at Mondelez International | Independent Director since 2021. Former executive at Johnson & Johnson and Procter & Gamble. | |
Karen W. Katz Board | Independent Director | Board Member at Under Armour and The RealReal | Independent Director since 2019. Former CEO of Neiman Marcus Group. | |
Kurt J. Hilzinger Board | Chairman of the Board | Partner at Court Square Capital Partners; Board Member at Outlook Therapeutics | Chairman of Humana's Board since 2014. Previously President and COO of AmerisourceBergen. | |
Marcy S. Klevorn Board | Independent Director | Board Member at Northern Trust Corporation and Cerence Inc. | Independent Director since 2021. Former Chief Transformation Officer at Ford Motor Company. |
-
Given the higher inpatient admissions observed in the latter half of the second quarter and continuing into July, can you provide more details on the specific steps you are taking to mitigate this pressure, and how confident are you that these measures will effectively offset the inpatient cost overruns going forward?
-
You mentioned that achieving normalized margins in your Medicare Advantage business will take multiple years due to regulatory constraints and TBC limitations; can you elaborate on the specific challenges you face and what strategies you have in place to accelerate margin recovery before 2027? ,
-
With the planned exits from certain markets due to unprofitable plans, how do you anticipate these exits will impact your overall membership growth and earnings in 2025, especially considering the potential retention of members through other plan options? ,
-
Regarding your cost management efforts, you've highlighted investments in automation and technology, including partnerships with Google for AI initiatives; can you provide specific examples of how these investments are translating into measurable cost reductions and operational efficiencies, and what is the expected timeline for realizing these benefits? ,
-
There have been concerns that extensive cost-cutting measures might have affected your ability to respond swiftly to emerging cost pressures, such as the higher inpatient costs attributed to the two-midnight rule; how do you address this concern, and what safeguards are in place to ensure essential capabilities are not compromised by cost reductions?
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Centers for Medicare & Medicaid Services (Florida Medicare Advantage) | Provides Medicare Advantage coverage to approximately 924,800 members | Medicare Advantage | Contributed 14% of 2024 total premiums and services revenue |
Department of Defense (TRICARE T2017 East Region) | Provided TRICARE coverage to approximately 6 million beneficiaries in 32 states | Military Services | Contributed 1% of 2024 total premiums and services revenue |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Primary Care Organization (PCO) | 2024 | Humana’s PCO acquisition involved acquiring up to 50 centers with a plan to consolidate some locations in the first half of 2025 to drive synergy and accelerate growth, targeting a patient panel of 350,000–360,000 by year-end. |
Intrepid | 2024 | The Intrepid acquisition was completed in Q3 2024, adding 30 net new branch locations in certificate of need states and over 200 field clinicians, along with key referral and patient relationships that enhance Humana’s Home business. |
Health and Wellness-related Businesses | 2023 | In 2023, Humana acquired various health and wellness-related businesses for approximately $223 million in net cash consideration, increasing goodwill by $398 million (recorded using Level 3 inputs), though individually these deals did not materially impact overall financial results. |
Health and Wellness-related Businesses | 2022 | The 2022 acquisitions involved various health and wellness businesses for roughly $293 million (net of cash received), with integrated operations into Humana’s financial statements and partial goodwill amortization for tax purposes, while not materially affecting financial performance. |
Recent press releases and 8-K filings for HUM.
- Humana Inc. completed the issuance of an additional $250 million 5.375% Senior Notes due 2031, augmenting the existing $1.25 billion issuance to a total of $1.5 billion in outstanding debt ( ).
- The offering, priced at 99.941% (plus accrued interest), was executed under an underwriting agreement with J.P. Morgan Securities LLC and Barclays Capital Inc., with net proceeds estimated at approximately $247 million for general corporate purposes ( ).